Corgentech

Biotech company developing genetic therapies for cardiovascular and other diseases

Corgentech, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States. It focuses on treatment of cardiovascular disease, inflammatory diseases, and cancer. The company is developing transcription factor decoys and aptamers that treat disease through the regulation of gene expression. Its product candidates include E2F Decoy, a combination drug and delivery device, for the prevention of coronary artery bypass graft failure; NF-kB Decoy, which is used for the treatment of Eczema; and HIF Decoy for the treatment of cancer. The company has collaboration agreements with Bristol-Myers Squibb Company for the development and commercialization of E2F Decoy, a combination drug and delivery device, for the prevention of coronary artery bypass graft failure. It also has collaboration agreements with The Board of Trustees of the Leland Stanford Junior University; The Brigham and Women''s Hospital, Inc.; Cyclacel Limited; and Avecia Limited. The company was co-founded by Victor J. Dzau and Michael J. Mann in 1999. Corgentech is headquartered in San Francisco, California.